logo

Genocea Biosciences, Inc. (GNCA)



Trade GNCA now with
  Date
  Headline
9/22/2020 7:37:10 AM Genocea: FDA Accepts GEN-011 IND Application
9/17/2020 3:15:56 AM Genocea Presents Follow-up Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial
5/19/2020 7:33:43 AM Genocea Enters Material Transfer And License Option Agreement With Shionogi For Proprietary GEN-003 HSV-2 Antigens
1/2/2019 8:08:24 AM Genocea Completes Enrollment In Part A Of Phase 1/2a Trial For Neoantigen Vaccine Candidate GEN-009
11/1/2018 8:15:26 AM Genocea Q3 Net Loss $7.8 Mln Vs Net Loss $16.9 Mln Last Year
10/1/2018 7:34:30 AM Genocea Names Thomas Davis Chief Medical Officer And Derek Meisner General Counsel
8/2/2018 8:23:41 AM Genocea Q2 Net Loss $4.4 Mln Vs Loss Of $15.4 Mln Last Year
5/10/2018 8:12:06 AM Genocea Q1 Loss Per Share $0.21 Vs Loss $0.48 Last Year
4/30/2018 8:08:49 AM Genocea Files Investigational NDA For Neoantigen Cancer Vaccine Candidate GEN-009
2/15/2018 8:02:30 AM Genocea Biosciences Posts Q4 Net Loss Of $10.73 Mln Or $0.37/share
1/17/2018 8:42:55 AM Genocea Biosciences Reports Pricing Of $55 Mln Concurrent Public Offerings